Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Total Liabilities for 5 consecutive years, with $196.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 37.93% year-over-year to $196.0 million, compared with a TTM value of $196.0 million through Dec 2025, up 37.93%, and an annual FY2025 reading of $196.0 million, up 37.93% over the prior year.
  • Total Liabilities was $196.0 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $177.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $196.0 million in Q4 2025 and bottomed at $38.8 million in Q3 2021.
  • Average Total Liabilities over 5 years is $93.0 million, with a median of $76.9 million recorded in 2022.
  • The sharpest move saw Total Liabilities surged 95.68% in 2022, then dropped 18.47% in 2023.
  • Year by year, Total Liabilities stood at $47.8 million in 2021, then soared by 33.0% to $63.5 million in 2022, then soared by 37.72% to $87.5 million in 2023, then surged by 62.45% to $142.1 million in 2024, then surged by 37.93% to $196.0 million in 2025.
  • Business Quant data shows Total Liabilities for KNSA at $196.0 million in Q4 2025, $177.0 million in Q3 2025, and $166.1 million in Q2 2025.